126 related articles for article (PubMed ID: 21076459)
1. Luminal cytokeratin expression profiles of breast papillomas and papillary carcinomas and the utility of a cytokeratin 5/p63/cytokeratin 8/18 antibody cocktail in their distinction.
Reisenbichler ES; Balmer NN; Adams AL; Pfeifer JD; Hameed O
Mod Pathol; 2011 Feb; 24(2):185-93. PubMed ID: 21076459
[TBL] [Abstract][Full Text] [Related]
2. The predictive ability of a CK5/p63/CK8/18 antibody cocktail in stratifying breast papillary lesions on needle biopsy: an algorithmic approach works best.
Reisenbichler ES; Adams AL; Hameed O
Am J Clin Pathol; 2013 Dec; 140(6):767-79. PubMed ID: 24225742
[TBL] [Abstract][Full Text] [Related]
3. An analysis of cyclin D1, cytokeratin 5/6 and cytokeratin 8/18 expression in breast papillomas and papillary carcinomas.
Wang Y; Zhu JF; Liu YY; Han GP
Diagn Pathol; 2013 Jan; 8():8. PubMed ID: 23327593
[TBL] [Abstract][Full Text] [Related]
4. The role of immunohistochemistry for smooth-muscle actin, p63, CD10 and cytokeratin 14 in the differential diagnosis of papillary lesions of the breast.
Tse GM; Tan PH; Lui PC; Gilks CB; Poon CS; Ma TK; Law BK; Lam WW
J Clin Pathol; 2007 Mar; 60(3):315-20. PubMed ID: 16698948
[TBL] [Abstract][Full Text] [Related]
5. Cytokeratins in papillary lesions of the breast: is there a role in distinguishing intraductal papilloma from papillary ductal carcinoma in situ?
Tan PH; Aw MY; Yip G; Bay BH; Sii LH; Murugaya S; Tse GM
Am J Surg Pathol; 2005 May; 29(5):625-32. PubMed ID: 15832086
[TBL] [Abstract][Full Text] [Related]
6. Use of p63 and CD10 in the differential diagnosis of papillary neoplasms of the breast.
de Moraes Schenka NG; Schenka AA; de Souza Queiroz L; de Almeida Matsura M; Vassallo J; Alvarenga M
Breast J; 2008; 14(1):68-75. PubMed ID: 18086274
[TBL] [Abstract][Full Text] [Related]
7. Keratin Expression Patterns in Stromal Cells of Benign Sclerosing Lesions of the Breast: A Potential Diagnostic Pitfall.
Oh EY; Collins LC
Arch Pathol Lab Med; 2015 Sep; 139(9):1143-8. PubMed ID: 25989286
[TBL] [Abstract][Full Text] [Related]
8. Papillary neoplasia of the breast: immunohistochemically defined myoepithelial cells in the diagnosis of benign and malignant papillary breast neoplasms.
Raju UB; Lee MW; Zarbo RJ; Crissman JD
Mod Pathol; 1989 Nov; 2(6):569-76. PubMed ID: 2479944
[TBL] [Abstract][Full Text] [Related]
9. Comparison of immunohistochemical staining in breast papillary neoplasms of cytokeratin 5/6 and p63 in core needle biopsies and surgical excisions.
Koo JS; Kim MJ; Kim EK; Park BW
Appl Immunohistochem Mol Morphol; 2012 Mar; 20(2):108-15. PubMed ID: 22553810
[TBL] [Abstract][Full Text] [Related]
10. Intracystic papillary carcinomas of the breast: a reevaluation using a panel of myoepithelial cell markers.
Collins LC; Carlo VP; Hwang H; Barry TS; Gown AM; Schnitt SJ
Am J Surg Pathol; 2006 Aug; 30(8):1002-7. PubMed ID: 16861972
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic evaluation of papillary lesions of the breast on core biopsy.
Pathmanathan N; Albertini AF; Provan PJ; Milliken JS; Salisbury EL; Bilous AM; Byth K; Balleine RL
Mod Pathol; 2010 Jul; 23(7):1021-8. PubMed ID: 20473278
[TBL] [Abstract][Full Text] [Related]
12. [Clinicopathologic and immunohistochemical study of 187 cases of intraductal papillary neoplasm of breast].
Zhang H; Xiong Y; Zhang S; Zhang Y; Wang YH; Li T
Zhonghua Bing Li Xue Za Zhi; 2011 Nov; 40(11):726-31. PubMed ID: 22336153
[TBL] [Abstract][Full Text] [Related]
13. The clinical use of a P63/cytokeratin7/18/cytokeratin5/14 antibody cocktail in diagnostic breast pathology.
Reisenbichler ES; Ross JR; Hameed O
Ann Diagn Pathol; 2014 Dec; 18(6):313-8. PubMed ID: 25224390
[TBL] [Abstract][Full Text] [Related]
14. Differential expression of cyclin D1 in breast papillary carcinomas and benign papillomas: an immunohistochemical study.
Saddik M; Lai R; Medeiros LJ; McCourty A; Brynes RK
Arch Pathol Lab Med; 1999 Feb; 123(2):152-6. PubMed ID: 10050790
[TBL] [Abstract][Full Text] [Related]
15. p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas.
Matos I; Dufloth R; Alvarenga M; Zeferino LC; Schmitt F
Virchows Arch; 2005 Oct; 447(4):688-94. PubMed ID: 16012853
[TBL] [Abstract][Full Text] [Related]
16. Observer variability in the histopathological reporting of core biopsies of papillary breast lesions is reduced by the use of immunohistochemistry for CK5/6, calponin and p63.
Douglas-Jones A; Shah V; Morgan J; Dallimore N; Rashid M
Histopathology; 2005 Aug; 47(2):202-8. PubMed ID: 16045782
[TBL] [Abstract][Full Text] [Related]
17. p63 expression in benign and malignant breast lesions.
Stefanou D; Batistatou A; Nonni A; Arkoumani E; Agnantis NJ
Histol Histopathol; 2004 Apr; 19(2):465-71. PubMed ID: 15024707
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical staining of papillary breast lesions.
Troxell ML; Masek M; Sibley RK
Appl Immunohistochem Mol Morphol; 2007 Jun; 15(2):145-53. PubMed ID: 17525625
[TBL] [Abstract][Full Text] [Related]
19. Myoepithelial cells in solid variant of intraductal papillary carcinoma of the breast: a potential diagnostic pitfall and a proposal of an immunohistochemical panel in the differential diagnosis with intraductal papilloma with usual ductal hyperplasia.
Moritani S; Ichihara S; Kushima R; Okabe H; Bamba M; Kobayashi TK; Hattori T
Virchows Arch; 2007 May; 450(5):539-47. PubMed ID: 17377808
[TBL] [Abstract][Full Text] [Related]
20. p63 correlates with both BRCA1 and cytokeratin 5 in invasive breast carcinomas: further evidence for the pathogenesis of the basal phenotype of breast cancer.
Ribeiro-Silva A; Ramalho LN; Garcia SB; Brandão DF; Chahud F; Zucoloto S
Histopathology; 2005 Nov; 47(5):458-66. PubMed ID: 16241993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
